[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538167":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":24,"responsibleParty":44,"collaborators":46,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":24,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":74,"whyStopped":24,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":24},{"fullName":5,"class":6},"Zuyderland Medisch Centrum","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide 2.4mg","ACTIVE_COMPARATOR","Patients in this group will receive the active comparator semaglutide 2.4mg. This is a medication which is distributed by an intramuscular injection once weekly.",[13],"Drug: Semaglutide 2.4 MG\u002F0.75 ML Subcutaneous Solution [WEGOVY]",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Patients in this group will receive the placebo. This is a placebo which is distributed by an intramuscular injection once weekly.",[19],"Other: Placebo",[21,25],{"type":6,"name":15,"description":22,"armGroupLabels":23,"otherNames":24},"The placebo will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.",[15],null,{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Semaglutide 2.4 MG\u002F0.75 ML Subcutaneous Solution [WEGOVY]","The semaglutide will be used in the allocated group in addition to our lifestyle program for the duration of 68 weeks in total.",[9],[31,32],"Wegovy","Semaglutide",[34],{"name":35,"affiliation":36,"role":37},"Jan Willem Greve, prof","Zuyderland Medical Center","PRINCIPAL_INVESTIGATOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":24,"email":43},"Marijn Jense, MD","CONTACT","+3188-4599719","m.jense@zuyderland.nl",{"type":45,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR",[47],{"name":48,"class":6},"Nederlandse Obesitas Kliniek","100538167","phase-4-semaglutide-24mg-for-low-responders-after-bariatric-surgery-100538167",false,"NCT06287307","Semaglutide 2.4mg for Low Responders After Bariatric Surgery","SEABAR","Inclusion Criteria:\n\n* BMI before surgery was ≥ 35.0 kg\u002Fm2\n* Patient is treated with group consultation at the NOK\n* Patient has undergone a primary (banded) RYGB or (banded) sleeve gastrectomy (SG)\n* Patient is in the lowest %TWL quartile, 3 months after surgery and will be enrolled in the plus module.\n\nExclusion Criteria:\n\n* Gastropareses or gastro-intestinal complaints after bariatric surgery\n* Type 1 or type 2 diabetes and\u002For diabetic retinopathy\n* Decreased renal function (creatinine clearance \\\u003C 30 ml\u002Fmin)\n* Liver failure (all)\n* Congestive heart failure or angina pectoris NYHA class III and IV\n* Malignancy in history\n* Pancreatitis (in history)\n* (expected) Pregnancy \u002F breast-feeding\n* Inflammatory Bowel Disease\n* Thyroid malignancy in history\n* Use of warfarin or other coumarin derivates","ALL","18 Years","75 Years",{"count":60,"type":61},152,"ESTIMATED","INTERVENTIONAL",[64],"PHASE4","In 20 - 30% of the patients, the low responders, sufficient weight loss is not achieved after bariatric surgery. Secondary and\u002For tertiary bariatric procedures can lead to successful weight loss and resolution of comorbid conditions though, morbidity and mortality rates of these procedures are high. Therefore, additional pharmacotherapy has been suggested. Semaglutide is one of the medications that might improve outcome in the post-bariatric population. Semaglutide is a Glucagon-like peptide-1 (GLP-1) receptor analogue developed to treat type 2 diabetes. It causes glucose-dependent insulin secretion, promotes satiety and inhibits glucagon secretion. In obese (non-bariatric) patients, semaglutide has shown to improve glycemic control, decrease blood pressure, lower cardiovascular risk, and decrease body weight.",[67,68,69],"Obesity","Obesity, Morbid","Weight Gain",[67,32,71,72,73],"GLP-1","Bariatric Surgery","Weight Loss","NOT_YET_RECRUITING","2024-02-22",{"date":77,"type":78},"2024-03-01","ACTUAL",{"date":80,"type":61},"2024-05",{"date":82,"type":61},"2026-09",{"name":5,"class":6}]